首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Molecular Therapy-methods & Clinical Development

Molecular Therapy-methods & Clinical Development杂志,由Cell Press出版,于2014年创刊,1 issue/year,出版语言English,ISSN:2329-0501,E-ISSN:2329-0501。

投稿咨询
Molecular Therapy-methods & Clinical Development
Molecular Therapy-methods & Clinical Development
Molecular Therapy-methods & Clinical Development
SCI SCIE

杂志介绍

JCR分区
Q2
中科院分区
2区
影响因子
4.533
CiteScore
7.7
期刊收录
SCI、SCIE

Molecular Therapy-methods & Clinical Development(中文译名:《分子治疗方法和临床开发》),ISSN:2329-0501,EISSN:2329-0501,是Cell Press出版的国际性学术期刊,创刊于2014年,以1 issue/year形式稳定发行,2026年总发文量约0篇。该刊采用OA开放访问,学科归属为Biochemistry, Genetics and Molecular Biology - Molecular Biology。该刊是医学、医学研究与实验领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达0,2025年期刊CiteScore为7.7,2025年期刊自引率约0%,在中科院期刊分区体系中位列医学大类2区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Molecular Therapy-methods & Clinical Development长期聚焦医学、医学研究与实验及相关产业的技术应用前沿,平均审稿周期12 Weeks,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、医学研究与实验领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USACHINA MAINLAND、England、France、GERMANY (FED REP GER)、Japan、Italy等为核心发文国家与地区;INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)HARVARD UNIVERSITY、STATE UNIVERSITY SYSTEM OF FLORIDA、UNIVERSITY OF WASHINGTON、UNIVERSITY OF CALIFORNIA SYSTEM、UNIVERSITY OF LONDON、UNIVERSITY OF PENNSYLVANIA等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
MEDICINE, RESEARCH & EXPERIMENTAL 医学:研究与实验
2区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
MEDICINE, RESEARCH & EXPERIMENTAL 医学:研究与实验
2区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
MEDICINE, RESEARCH & EXPERIMENTAL 医学:研究与实验
2区

中国学者近期发文

1
Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infectio

Author:Guo, Qi; Parikh, Keval; Zhang, Jian; Brinkley, Alexander; Chen, Grace; Jakramonpreeya, Natnicha; Zhen, Anjie; An, Dong Sung

Journal: MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT. 2025; Vol. 33, Issue 2, pp. -. DOI: 10.1016/j.omtm.2025.101486

2
Self-silencing adenovirus enables precise infectious titration of recombinant adeno-associated viral vector

Author:Fustinoni, Chloe; Liu, Xiang; Chen, Zhi; Cawood, Ryan; Valenti, Weimin; Patricio, Maria I.; Su, Weiheng

Journal: MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT. 2025; Vol. 33, Issue 2, pp. -. DOI: 10.1016/j.omtm.2025.101492

3
The clinical quality management system of advanced therapy medicinal products in the hospital setting: A scoping revie

Author:Shi, Junnan; Yang, Jinagya; Zheng, Yu; Wong, Phyllis Hio Hong; Hu, Hao; Ung, Carolina Oi Lam

Journal: MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT. 2025; Vol. 33, Issue 2, pp. -. DOI: 10.1016/j.omtm.2025.101485

4
Preclinical studies of an AAV8-CYP4V2 gene therapy VGR-R01 for the treatment of Bietti crystalline dystroph

Author:Luo, Wenjing; Guo, Lu; Lu, Liang; Huang, Nan; Tao, Yezheng; Zhang, Yufei; Cao, Yanrong; Tian, Shin-Shay; Zhao, Xiaoping; Zhu, Xi

Journal: MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT. 2025; Vol. 33, Issue 2, pp. -. DOI: 10.1016/j.omtm.2025.101460

5
Lipid nanoparticles: Composition, formulation, and applicatio

Author:Xu, Sijia; Hu, Zhenzhen; Song, Fenglin; Xu, Ying; Han, Xuexiang

Journal: MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT. 2025; Vol. 33, Issue 2, pp. -. DOI: 10.1016/j.omtm.2025.101463

6
Efficacy and preliminary safety assessment of EXG001-307 AAV gene therapy for spinal muscular atroph

Author:Song, Chunjuan; Wang, Qingzeng; Zhu, Peixin; Li, Junhui; Dai, Li; Hu, Wei; Yang, Wenshu; Zhang, Runyuan; Wang, Dandan; Li, Zhongwan; Chen, Shuyuan; Wang, Lijun; Ye, Guojie; Wu, Zhenhua

Journal: MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT. 2025; Vol. 33, Issue 2, pp. -. DOI: 10.1016/j.omtm.2025.101475

7
The combination of rAAV pseudo-lipid nanoparticle and triamcinolone acetonide enables multi-administration to live

Author:Gan, Chunmei; Leng, Mi; Liu, Yu; Zheng, Zhaoyue; He, Siwu; Qiao, Wen; Xiao, Lin; Xiao, Yao; Ye, Jingya; Zhou, Lixing; Zhou, Jiao; Xiao, Boduan; Zhao, Wenxin; Yang, Jiamei; Wu, Aohan; Zhang, Huiyuan; Hu, Hongbo; Cen, Xiaobo; Qian, Zhiyong; Dong, Haohao; Valencia, C. Alexander; Dai, Lunzhi; Chow, Hoi Yee; Zhang, Lei; Dong, Biao

Journal: MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT. 2025; Vol. 33, Issue 1, pp. -. DOI: 10.1016/j.omtm.2024.101399

8
Intravenous esketamine in pediatric Rett syndrome: An open-label, early phase 1 pilot stud

Author:Li, Huiping; Liu, Shu; Lin, Caimei; Wu, Yuchao; Wu, Xiuping; Huang, Yukun; Wu, Yajun; Tong, Xiubin; Xu, Xiu

Journal: MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT. 2025; Vol. 33, Issue 1, pp. -. DOI: 10.1016/j.omtm.2025.101413

9
Silencing hepatic PCSK9 via novel chimeric AAV8 mitigates the progression of atherosclerosis by inhibiting inflammation in ApoE-/- mic

Author:Chen, Xiaocui; Sun, Minghui; Ma, Xiang; Ma, Yitong; Chen, Bangdang

Journal: MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT. 2025; Vol. 33, Issue 1, pp. -. DOI: 10.1016/j.omtm.2024.101390


在线咨询

Molecular Therapy-methods & Clinical Development

国际简称:MOL THER-METH CLIN D参考译名:分子治疗方法和临床开发

年发文量:0 CiteScore:7.7 是否预警:否 Gold OA文章占比:90.58% 研究类文章占比:94.59%

杂志社联系方式:50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, USA, MA, 02139

Molecular Therapy-methods & Clinical Development